tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RGNX Stock Latest News

Regenxbio price target lowered to $17 from $21 at RBC Capital
The FlyRegenxbio price target lowered to $17 from $21 at RBC Capital
8d ago
RGNX
Regenxbio price target lowered to $37 from $50 at Barclays
PremiumThe Fly
Regenxbio price target lowered to $37 from $50 at Barclays
8d ago
RGNX
REGENXBIO Reports Q2 2025 Financial Results and Progress
PremiumCompany Announcements
REGENXBIO Reports Q2 2025 Financial Results and Progress
8d ago
RGNX
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
PremiumThe Fly
Regenxbio launches program for surabgene lomparvovec in diabetic retinopathy
9d ago
ABBV
RGNX
RegenXBio and AbbVie Amend Collaboration Agreement
PremiumCompany Announcements
RegenXBio and AbbVie Amend Collaboration Agreement
9d ago
8K
RGNX
Regenxbio reports Q2 EPS ($1.38) vs. ($1.05) last year
PremiumThe FlyRegenxbio reports Q2 EPS ($1.38) vs. ($1.05) last year
9d ago
RGNX
Regenxbio says cash position to fund operations into early 2027
Premium
The Fly
Regenxbio says cash position to fund operations into early 2027
9d ago
RGNX
RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating
Premium
Ratings
RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating
29d ago
RGNX
Optimistic Buy Rating for RegenXBio Amidst RGX-202 Program’s Promising Advancements and Strategic Safety Measures
PremiumRatings
Optimistic Buy Rating for RegenXBio Amidst RGX-202 Program’s Promising Advancements and Strategic Safety Measures
2M ago
RGNX
RegenXBio’s Strategic Approach and Promising Outlook Earns Buy Rating
PremiumRatings
RegenXBio’s Strategic Approach and Promising Outlook Earns Buy Rating
2M ago
RGNX
RegenXBio Positioned for Success Amidst SRPT’s Elevidys Concerns: Analyst Recommends Buy
PremiumRatings
RegenXBio Positioned for Success Amidst SRPT’s Elevidys Concerns: Analyst Recommends Buy
2M ago
RGNX
BofA expects no changes for Regenxbio regimen after competitor safety issue
PremiumThe Fly
BofA expects no changes for Regenxbio regimen after competitor safety issue
2M ago
RGNX
SRPT
Regenxbio files to sell 268,096 shares of common stock for holders
PremiumThe FlyRegenxbio files to sell 268,096 shares of common stock for holders
2M ago
RGNX
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
Premium
Ratings
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism
2M ago
RGNX
Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
Premium
Ratings
Promising Interim Data and Accelerated Approval Pathway Drive Buy Rating for RegenXBio’s RGX-202
2M ago
RGNX
RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
PremiumRatings
RegenXBio: Promising Gene Therapy Developments and Strong Financial Position Support Buy Rating
2M ago
RGNX
Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial
PremiumThe Fly
Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial
2M ago
RGNX
RegenXBio Holds 2025 Annual Stockholders Meeting
PremiumCompany Announcements
RegenXBio Holds 2025 Annual Stockholders Meeting
2M ago
8K
RGNX
RegenXBio’s Strengthened Financial Position and Growth Prospects Drive Buy Rating
PremiumRatings
RegenXBio’s Strengthened Financial Position and Growth Prospects Drive Buy Rating
3M ago
RGNX
RegenXBio Secures $250M Royalty Monetization Deal
PremiumCompany AnnouncementsRegenXBio Secures $250M Royalty Monetization Deal
3M ago
8K
RGNX
Regenxbio signs strategic royalty monetization agreement for up to $250M
Premium
The Fly
Regenxbio signs strategic royalty monetization agreement for up to $250M
3M ago
RGNX
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
Premium
Company Announcements
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year
3M ago
RGNX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >